Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer

Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1635-9. doi: 10.1002/anie.201006115. Epub 2011 Jan 7.

Authors

Brendan L Wilkinson¹, Stephanie Day, Lara R Malins, Vasso Apostolopoulos, Richard J Payne

Affiliation

¹ School of Chemistry, The University of Sydney, New South Wales 2006, Australia.

PMID: 21308921
DOI: 10.1002/anie.201006115

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / chemistry
Amino Acid Sequence
Animals
Cancer Vaccines / chemical synthesis
Cancer Vaccines / chemistry*
Cancer Vaccines / immunology
Cell Line, Tumor
Dipeptides / chemistry*
Dipeptides / immunology
Glycosylation
Humans
Immunoglobulin G / metabolism
Lipoproteins / chemistry*
Lipoproteins / immunology
Mice
Mice, Inbred C57BL
Molecular Sequence Data
Mucin-1 / chemistry*
Mucin-1 / immunology
Toll-Like Receptor 2 / agonists*
Toll-Like Receptor 2 / metabolism

Substances

Adjuvants, Immunologic
Cancer Vaccines
Dipeptides
Immunoglobulin G
Lipoproteins
Mucin-1
Toll-Like Receptor 2
2,3-bis-(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinylserine